JP2020504716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504716A5 JP2020504716A5 JP2019531160A JP2019531160A JP2020504716A5 JP 2020504716 A5 JP2020504716 A5 JP 2020504716A5 JP 2019531160 A JP2019531160 A JP 2019531160A JP 2019531160 A JP2019531160 A JP 2019531160A JP 2020504716 A5 JP2020504716 A5 JP 2020504716A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022096439A JP2022137047A (ja) | 2016-12-22 | 2022-06-15 | ヒストンメチルトランスフェラーゼ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438121P | 2016-12-22 | 2016-12-22 | |
| US62/438,121 | 2016-12-22 | ||
| PCT/US2017/067855 WO2018119208A1 (en) | 2016-12-22 | 2017-12-21 | Histone methyltransferase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096439A Division JP2022137047A (ja) | 2016-12-22 | 2022-06-15 | ヒストンメチルトランスフェラーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504716A JP2020504716A (ja) | 2020-02-13 |
| JP2020504716A5 true JP2020504716A5 (enExample) | 2021-02-04 |
| JP7091336B2 JP7091336B2 (ja) | 2022-06-27 |
Family
ID=60972497
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531160A Expired - Fee Related JP7091336B2 (ja) | 2016-12-22 | 2017-12-21 | ヒストンメチルトランスフェラーゼ阻害剤 |
| JP2022096439A Pending JP2022137047A (ja) | 2016-12-22 | 2022-06-15 | ヒストンメチルトランスフェラーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096439A Pending JP2022137047A (ja) | 2016-12-22 | 2022-06-15 | ヒストンメチルトランスフェラーゼ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10829452B2 (enExample) |
| EP (2) | EP3558971B1 (enExample) |
| JP (2) | JP7091336B2 (enExample) |
| AR (1) | AR110443A1 (enExample) |
| ES (2) | ES2981507T3 (enExample) |
| TW (1) | TW201829386A (enExample) |
| WO (1) | WO2018119208A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558971B1 (en) * | 2016-12-22 | 2022-02-23 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
| CN118021814A (zh) | 2017-04-21 | 2024-05-14 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| US20210260040A1 (en) * | 2017-10-18 | 2021-08-26 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in treating or preventing blood disorders |
| JP2021500327A (ja) * | 2017-10-18 | 2021-01-07 | エピザイム，インコーポレイティド | 免疫療法にｅｈｍｔ２阻害剤を使用する方法 |
| CN112105796B (zh) | 2018-03-09 | 2024-10-25 | 斯伦贝谢技术有限公司 | 集成井施工系统操作 |
| CN111196817B (zh) * | 2018-11-19 | 2021-06-11 | 四川大学华西医院 | 作为brpf1抑制剂的三环化合物 |
| WO2020168927A1 (zh) * | 2019-02-19 | 2020-08-27 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
| CN111620818B (zh) * | 2019-02-28 | 2023-09-29 | 暨南大学 | 8,9-二甲氧基啡啶类化合物及其应用 |
| CN116710431A (zh) * | 2020-11-19 | 2023-09-05 | 泰洛治疗公司 | 小分子化合物和组合物 |
| WO2022115377A1 (en) * | 2020-11-24 | 2022-06-02 | Amgen Inc. | Tricyclic carboxamide derivatives as prmt5 inhibitors |
| EP4284781A1 (en) | 2021-01-27 | 2023-12-06 | Vandria SA | Urolithin derivatives and methods of use thereof |
| CN113004294B (zh) * | 2021-03-08 | 2023-01-17 | 温州大学新材料与产业技术研究院 | 一种四氢呋喃并1,4-二氢喹啉类化合物及其制备方法和应用 |
| CN114573569B (zh) * | 2022-03-30 | 2023-07-04 | 邦恩泰(山东)生物医药科技集团股份有限公司 | 一种异喹啉类化合物的制备方法 |
| CN117903150A (zh) * | 2024-01-11 | 2024-04-19 | 中国科学技术大学 | 一种烯基取代的多环氮杂环的合成方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| KR100826817B1 (ko) | 2000-03-15 | 2008-05-02 | 사노피-아벤티스 도이칠란트 게엠베하 | 치환된 베타-카볼린 |
| CA2510375A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| ES2406730T3 (es) * | 2003-08-27 | 2013-06-07 | 3M Innovative Properties Company | Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi |
| AR046046A1 (es) | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
| EP1846419B1 (en) | 2005-02-09 | 2014-04-16 | 3M Innovative Properties Company | Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines |
| CA2974246C (en) * | 2006-09-01 | 2020-02-25 | Senhwa Biosciences, Inc. | Tricyclic heteroaryl compounds and their use as protein modulators |
| WO2008101682A2 (en) | 2007-02-22 | 2008-08-28 | Syngenta Participations Ag | Iminipyridine derivatives and their uses as microbiocides |
| WO2009085185A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| EA018068B1 (ru) | 2008-03-03 | 2013-05-30 | Айрм Ллк | Соединения и композиции в качестве модуляторов активности tlr |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2010056038A2 (ko) * | 2008-11-11 | 2010-05-20 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| EP2485731B1 (en) | 2009-10-06 | 2016-05-11 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as pdk1 inhibitors |
| US20130231360A1 (en) | 2010-04-22 | 2013-09-05 | The Brigham And Women S Hospital, Inc. | Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases |
| JP2013533239A (ja) | 2010-06-25 | 2013-08-22 | ファキュルテ ユニヴェルシテール ノートル−ダム ド ラ ペ | 増殖性疾患の治療に有用なβカルボリン誘導体 |
| PT2688887E (pt) | 2011-03-23 | 2015-07-06 | Amgen Inc | Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3 |
| KR101827444B1 (ko) | 2012-02-01 | 2018-02-08 | 제일약품주식회사 | 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법 |
| US10662193B2 (en) | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
| US9284272B2 (en) * | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
| DK3154957T3 (da) * | 2014-06-16 | 2020-02-17 | Fundacion Para La Investig Medica Aplicada | Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser |
| CN108431000A (zh) * | 2015-11-16 | 2018-08-21 | 基础应用医学研究基金会 | 作为dna甲基转移酶抑制剂的新型化合物 |
| EP3558971B1 (en) * | 2016-12-22 | 2022-02-23 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
-
2017
- 2017-12-21 EP EP17829543.2A patent/EP3558971B1/en active Active
- 2017-12-21 US US15/850,389 patent/US10829452B2/en active Active
- 2017-12-21 TW TW106145167A patent/TW201829386A/zh unknown
- 2017-12-21 JP JP2019531160A patent/JP7091336B2/ja not_active Expired - Fee Related
- 2017-12-21 ES ES22153996T patent/ES2981507T3/es active Active
- 2017-12-21 WO PCT/US2017/067855 patent/WO2018119208A1/en not_active Ceased
- 2017-12-21 EP EP22153996.8A patent/EP4063358B1/en active Active
- 2017-12-21 ES ES17829543T patent/ES2910108T3/es active Active
- 2017-12-22 AR ARP170103662A patent/AR110443A1/es unknown
-
2020
- 2020-11-04 US US17/089,239 patent/US11713299B2/en active Active
-
2022
- 2022-06-15 JP JP2022096439A patent/JP2022137047A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504716A5 (enExample) | ||
| US11571424B2 (en) | Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them | |
| JP2020125349A5 (enExample) | ||
| CN103124729B (zh) | 作为Axl抑制剂的药物活性化合物 | |
| JP6654646B2 (ja) | Ｔａｍ ｒｔｋインヒビターとしてのキノリン誘導体 | |
| JP2016523973A5 (enExample) | ||
| RU2017118160A (ru) | Фармацевтическое соединение | |
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| RU2015143717A (ru) | 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия | |
| WO2018214867A9 (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| TW200403210A (en) | Benzamide derivatives | |
| JP6969800B2 (ja) | 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体 | |
| JP2017534569A (ja) | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 | |
| CN117062819A (zh) | 多环化合物及其用途 | |
| JP2021525270A (ja) | Ａｘｌ／ｍｅｒ ｒｔｋおよびｃｓｆ１ｒの阻害剤としてのキノリン誘導体 | |
| WO2004087679A1 (en) | 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases | |
| JP2019522681A5 (enExample) | ||
| JP6913955B2 (ja) | ＰＩ３Ｋ／ｍＴＯＲ阻害剤としての溶融キノリン化合物 | |
| JPWO2021076691A5 (enExample) | ||
| KR20230035070A (ko) | Atr 억제제 및 이의 용도 | |
| RU2021136789A (ru) | Триарильные соединения для лечения pd-l1 заболеваний | |
| WO2016050016A1 (zh) | 作为激酶抑制剂的取代杂环化合物及其制备方法和用途 | |
| TWI324516B (en) | Fused tri-heterocyclic compounds | |
| TW201912636A (zh) | 泊馬度胺衍生物及其製備方法 | |
| JP2015534975A5 (enExample) |